IgG from myeloperoxidase-antineutrophil cytoplasmic antibody-positive patients stimulates greater activation of primed neutrophils than IgG from proteinase 3-antineutrophil cytosplasmic antibody-positive patients.
about
Anti-cytokine therapies for primary systemic necrotizing vasculitisNeutrophil-Mediated Regulation of Innate and Adaptive Immunity: The Role of MyeloperoxidaseAntineutrophil cytoplasmic antibody positivity in IgG4-related disease: A case report and review of the literatureReduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib.The role of biologics in treatment of ANCA-associated vasculitis.Regulation of human neutrophil apoptosis and lifespan in health and disease.Chimeric antibodies to proteinase 3 of IgG1 and IgG3 subclasses induce different magnitudes of functional responses in neutrophils.Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib.Anti-neutrophil cytoplasm antibody IgG subclasses in Wegener's granulomatosis: a possible pathogenic role for the IgG4 subclass.Follow-up of avidity and titer of anti-myeloperoxidase antibodies in sera from patients with primary ANCA-associated vasculitis.Anti-myeloperoxidase and anti-cathepsin G antibodies in sulphonamide hypersensitivity.Trafficking of QD-conjugated MPO-ANCA in murine systemic vasculitis and glomerulonephritis model mice.Pathogenetic and Clinical Aspects of Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitides.Impact of anti-glomerular basement membrane antibodies and glomerular neutrophil activation on glomerulonephritis in experimental myeloperoxidase-antineutrophil cytoplasmic antibody vasculitis.
P2860
Q24241555-B1BC79E7-B24C-4CB6-8776-1F1306B8531DQ26767149-BBFADF0F-57C5-4685-837B-3660BA7C1F7DQ33590579-76DF53EC-6784-4CCF-8B98-01DDF75DE3F4Q35875744-7B07F84C-32C9-45E1-9C27-0971878AB35FQ37950904-02B44467-FAE7-4A3D-AF55-1F2528D4526EQ38256353-0415F77C-BBDA-4F0B-8DE9-90DB306AA285Q42410335-A3A0C6CC-3157-43A8-A233-B6DCF9ECA0FCQ44282395-6F59C8D5-6EF5-450E-9055-244A2F5A0122Q45063516-F736AFA3-08F9-4C88-861B-53FF6A1BE800Q46081324-066C0F0A-14C0-41BF-A8AD-D41DC519559AQ46919841-49DCDF7D-4773-495D-B76A-DCB295409AAFQ50975645-7D4873FD-E22C-4AE0-9B57-CC1319EB97EEQ52311683-E3144E9E-43F3-4775-B820-200AB8731C7CQ52901866-99F4D5E7-2BA6-418C-8A80-B75BC34B3F26
P2860
IgG from myeloperoxidase-antineutrophil cytoplasmic antibody-positive patients stimulates greater activation of primed neutrophils than IgG from proteinase 3-antineutrophil cytosplasmic antibody-positive patients.
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
IgG from myeloperoxidase-antin ...... ic antibody-positive patients.
@ast
IgG from myeloperoxidase-antin ...... ic antibody-positive patients.
@en
IgG from myeloperoxidase-antin ...... ic antibody-positive patients.
@nl
type
label
IgG from myeloperoxidase-antin ...... ic antibody-positive patients.
@ast
IgG from myeloperoxidase-antin ...... ic antibody-positive patients.
@en
IgG from myeloperoxidase-antin ...... ic antibody-positive patients.
@nl
prefLabel
IgG from myeloperoxidase-antin ...... ic antibody-positive patients.
@ast
IgG from myeloperoxidase-antin ...... ic antibody-positive patients.
@en
IgG from myeloperoxidase-antin ...... ic antibody-positive patients.
@nl
P2093
P2860
P1476
IgG from myeloperoxidase-antin ...... ic antibody-positive patients.
@en
P2093
P2860
P304
P356
10.1002/1529-0131(200104)44:4<921::AID-ANR149>3.0.CO;2-4
P577
2001-04-01T00:00:00Z